51cg

Postgraduate research opportunities Targeted lipid nanoparticles for immunotherapy applications

Apply

Key facts

  • Opens: Monday 16 November 2026
  • Number of places: 2
  • Duration: 48 months

Overview

This PhD project will investigate the development of targeted lipid nanoparticle (LNP) delivery systems for in vivo expression of therapeutic antibodies with antitumour activity. The research will focus on engineering and evaluating LNP formulations capable of selectively targeting tumour-associated cells, enabling localised antibody production within the tumour microenvironment.
Back to opportunity

Eligibility

The successful candidate will hold an upper second class UK degree or equivalent in Biology, Biochemistry, Biomedical Engineering, or Chemistry, or any other relevant discipline.

THE Awards 2019: UK University of the Year Winner
Back to opportunity

Project Details

This PhD project will develop targeted lipid nanoparticle (LNP) systems capable of delivering messenger RNA (mRNA) encoding therapeutic antibodies directly to tumour-associated cells, enabling in vivo antibody production for cancer immunotherapy. The student will design and optimise antibody-encoding mRNA constructs and formulate LNPs with favourable physicochemical properties for efficient delivery and expression.

During the early stages of the project, a library of LNP formulations will be developed and characterised for particle size, encapsulation efficiency, stability, and transfection performance. Tumour-targeting strategies, including ligand-functionalised nanoparticles directed towards cancer cells, cancer-associated fibroblasts, or tumour-associated macrophages, will then be investigated to enhance the specificity and localisation of antibody expression within the tumour microenvironment.

Subsequent work will evaluate the anti-tumour efficacy of this platform using advanced in vitro and in vivo cancer models. The project will assess antibody production, cellular uptake, biodistribution, immune activation, and tumour growth inhibition, alongside detailed molecular and immunological profiling. In the later stages, the student will explore benchmarking against more advanced therapeutic approaches, including the delivery of checkpoint inhibitors or bispecific immune-engaging antibodies, while assessing manufacturability and translational potential.

By establishing a platform for localised antibody production within tumours, this research aims to overcome key limitations of conventional monoclonal antibody therapy, offering a potentially more effective, cost-efficient, and scalable strategy for the treatment of cancer.

Back to opportunity

Funding details

While there is no funding in place for opportunities marked "unfunded", there are lots of different options to help you fund postgraduate research. Visit funding your postgraduate research for links to government grants, research councils funding and more, that could be available.

Back to opportunity

Supervisors

Dr Rattray

Dr Zahra Rattray

Professor
51cg Institute of Pharmacy and Biomedical Sciences

View profile
Professor Perrie

Professor Yvonne Perrie

Head Of Institute
51cg Institute of Pharmacy and Biomedical Sciences

View profile
Back to course

Apply

Number of places: 2

To read how we process personal data, applicants can review our 'Privacy Notice for Student Applicants and Potential Applicants' on our Privacy notices' web page.

SIPBS (Biomedical Sciences)

Programme: SIPBS (Biomedical Sciences)

PhD
full-time
Start date: Oct 2026 - Sep 2027